AHA 2019 – The Medicines Company reaches for the stars
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Puretech’s cautionary tale about pivotal study read-across
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
AASLD 2019 – Assembly asks investors to keep the faith
Firmer evidence to support Assembly’s approach to vanquishing the hepatitis B virus will not emerge until next year, and rivals are not standing still in the meantime.
Reata’s worsened Cardinal results could still be good enough
The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.
Astrazeneca looks to power lupus effort over the finish line
Astrazeneca’s goal of bringing the second new lupus drug in over half a century to the market is a step closer, but all hangs on the FDA accepting mixed clinical data.
Roxadustat moves on to the regulators
A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…
SITC – the morning after the night before
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Ash 2019 preview – the first winner and losers emerge
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Takeda’s dengue data spell more bad news for Sanofi
Takeda’s pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi’s Dengvaxia look irrelevant.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.